| Bioactivity | Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| Name | Lusutrombopag-d13 |
| Formula | C29H19D13Cl2N2O5S |
| Molar Mass | 604.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |
Lusutrombopag-d13
CAS: F: C29H19D13Cl2N2O5S W: 604.63
Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) recep
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.